Фервекс

Quick links to important sections

Фервекс

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Фервекс

This section provides a summary of the medicine's core identity, composition, and classification.

Property Description
Active Ingredients Paracetamol, Pheniramine Maleate, Ascorbic Acid (Vitamin C)
Form Granules in a sachet for oral solution
Pharmacological Class Analgesic/Antipyretic, H₁-Antihistamine, Vitamin Supplement
Common Use Symptomatic relief of cold and flu
Origin France (Manufactured by UPSA)

Fervex is an over-the-counter (OTC) combination medicine used to manage the common symptoms associated with colds, flu, and rhinitis in adults (typically over 15 years old). It is distinctive because it is formulated as granules in a sachet to be dissolved in water, often taken warm, which provides immediate comfort for a sore throat and general chills.

The adult formulation combines three key active ingredients. The primary component is Paracetamol (Acetaminophen), a recognized pain reliever and fever reducer. Paracetamol is used for reducing mild to moderate pain and fever. This means the medicine can help reduce discomfort and bring down an elevated temperature.

Fervex also contains Pheniramine Maleate, which is an H₁-antihistamine. These agents work to counter the effects of histamine often involved in cold symptoms like sneezing and runny nose. Antihistamines are used in relieving nasal discharge and other mucosal symptoms of acute upper respiratory tract infections. This indicates the product is formulated to help dry up a persistent runny nose and stop sneezing. The final ingredient is Ascorbic Acid (Vitamin C), included as a supplement during febrile illness.

Regulatory References

  1. Acetaminophen: MedlinePlus Drug Information

What side effects are possible with Фервекс?

Possible Side Effects and Safety Information

The safety profile for this combination medicine, containing Paracetamol, Pheniramine Maleate, and Ascorbic Acid, is formally classified based on the documented adverse reactions of its active components. Regulatory documents categorize these effects by frequency and the body system affected.

Effects related to the Nervous System and Gastrointestinal System are common regulatory listings, primarily due to the Pheniramine Maleate component. These typically include drowsiness and reduced attention, which may be more pronounced at the beginning of treatment. Anticholinergic effects such as dry mouth and constipation are also noted in the official prescribing information.

The most significant safety constraint relates to the Paracetamol component, which carries a documented risk of Hepatotoxicity (severe liver damage), particularly with prolonged use or in cases of exceeding the recommended total daily limit. Severe adverse events, although classified as Very Rare or Not Known frequency, include serious Blood Disorders (e.g., thrombocytopenia) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome.

Official safety cautions address specific patient groups. Older adults may be more susceptible to side effects like sedation, dizziness, confusion, and urinary retention. Furthermore, the medicine is officially contraindicated in patients with severe liver disease (severe hepatocellular insufficiency) and in individuals with pre-existing conditions like closed-angle glaucoma or prostatic hypertrophy due to the effects of the antihistamine component.

Overdose and Emergency Response

The official regulatory profile for Fervex overdose is defined by the toxicological risks associated with its active components, Paracetamol and Pheniramine Maleate.

When Immediate Medical Help is Required

Immediate medical attention must be sought or a Poison Control Center contacted right away in any suspected overdose scenario. This urgent action is mandated even if the individual does not notice any signs or symptoms at the time of exposure. Taking multiple daily doses in a single administration is specifically cited in regulatory documents as a circumstance requiring immediate assistance.

Documented Manifestations and Severe Outcomes

Overdose carries the potential for severe, life-threatening outcomes, primarily due to Paracetamol-induced toxicity. Initial documented manifestations may include non-specific signs such as nausea, vomiting, and epigastric pain. The most severe outcomes are severe liver damage (hepatotoxicity), which can progress to fulminant hepatic failure, acute renal failure, and ultimately coma or death. The Pheniramine component contributes specific symptoms, including agitation, disorientation, hallucinations, and peripheral anticholinergic signs like dryness of mouth.

Management and Monitoring

Management requires hospital observation and procedural steps, including the administration of the specific antidote for Paracetamol toxicity, N-acetylcysteine (NAC). Monitoring involves serial laboratory tests, such as serum paracetamol concentration and liver function tests, to assess risk and guide treatment. Increased risk of severity is noted for patients with pre-existing conditions like severe hepatic or renal impairment.

Therapeutic Uses of Фервекс

What Фервекс Treats: Main Uses and Benefits

Fervex is relevant in contexts marked by increased discomfort or tension, assists in managing symptom clusters that may become intense or disruptive during acute viral illness. This combination is considered relevant for the short-term symptomatic management of fever and pain associated with conditions like rhinopharyngitis.

The medication is commonly used to help with headache, body aches, and elevated body temperature, and is applied in addressing symptoms related to inflammatory or irritative states, such as a frequent runny nose and sneezing. Applied in clinical settings that involve acute symptom patterns, this approach is relevant when supportive symptom management is appropriate to address symptoms that interfere with daily functioning. This support helps patients cope more steadily with difficult episodes, and may assist with maintaining functional stability.

“It is commonly used across conditions presenting with acute episodes and helps improve day-to-day comfort during symptomatic periods.”


Quick Fact: Relief for Co-Occurring Symptoms

Fervex is used across domains involving both symptoms related to systemic imbalance (pain and fever) and symptoms related to heightened physiological activity (runny nose, sneezing), assisting in easing the overall symptom load when they appear together.

Regulatory References

  1. Rwanda FDA Summary of Product Characteristics

Eligibility and Restrictions for Use

This information details the official population eligibility and non-eligibility for Fervex (Paracetamol/Ascorbic Acid/Pheniramine Maleate) as specified in regulatory documents such as the Summary of Product Characteristics (SmPC).

Contraindications (Must Not Use)

Population/Condition Regulatory Status
Age Children under 15 years old are contraindicated.
Severe Organ Function Individuals with severe liver disease (severe hepatocellular insufficiency) are strictly contraindicated due to the Paracetamol component.
Comorbidities Contraindicated for individuals at risk of angle-closure glaucoma and those with a risk of urinary retention linked to urethro-prostatic disorders.
Allergies Known hypersensitivity to any of the active substances or excipients is an exclusion criterion.
Metabolic Disorders Phenylketonuria (for sugar-free formulations containing aspartame) and certain hereditary sugar intolerances (for sucrose-containing formulations) are contraindications.

Restricted or Conditional Use

Use of Fervex requires caution and may be restricted by a healthcare professional in cases of mild to moderate liver or kidney insufficiency, chronic alcoholism, chronic malnutrition, dehydration, or hypovolemia. The elderly require caution due to potential increased sensitivity to certain effects. Pregnant and breastfeeding women are generally not recommended to use this medicine.


Official Eligibility Summary: The medicine is primarily allowed for adults and adolescents aged 15 and over, provided none of the documented absolute contraindications (severe liver disease, glaucoma risk, severe urinary difficulties, or hypersensitivity) are present. The official profile classifies exclusions as absolute (Contraindicated) or risk-based (Not Recommended/Conditional Use).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Fervex, based on regulatory labeling for its active components: Paracetamol, Pheniramine Maleate, and Ascorbic Acid.


Contraindicated Combinations and Exposure Restrictions

Regulatory documentation explicitly prohibits co-administration with other medicinal products containing Paracetamol to prevent the risk of overdose and liver damage. Fervex is also formally contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of potentiation. The consumption of alcohol (ethanol) is advised against, as it enhances the sedative effect of Pheniramine Maleate and increases the risk of Paracetamol-related hepatotoxicity.

Pharmacodynamic and Metabolic Effects

Co-administering Fervex with other CNS Depressants (including hypnotics and opioids) results in an additive pharmacodynamic effect, leading to increased sedation and reduced alertness. Use with Atropine-like substances may cause additive anticholinergic effects, such as urinary retention.

Exposure-modifying agents include Probenecid, which decreases Paracetamol clearance. Co-use with Hepatic Enzyme Inducers (like Rifampicin or Phenobarbital) increases the risk of toxic metabolite formation. For patients taking Vitamin K Antagonists (e.g., Warfarin), prolonged, high-dose Paracetamol use requires monitoring for increased bleeding risk.

Administration Constraints

A specific timing constraint exists for Cholestyramine, which reduces Paracetamol absorption. Administration must be separated from Cholestyramine by at least one hour before or four hours after. Furthermore, interaction risks are officially noted as being of greater clinical significance in populations with hepatic impairment or chronic alcoholism.

Mechanism of Action

Фервекс is a combination formulation consisting of three pharmacologically active components: paracetamol, phenylephrine hydrochloride, and ascorbic acid.

Paracetamol (Acetaminophen) primarily acts within the central nervous system (CNS). Its mechanism involves the inhibition of prostaglandin synthesis, likely by modulating the peroxidase function of Cyclooxygenase (COX) enzymes, particularly in the brain and spinal cord. This action reduces levels of Prostaglandin E2 ( PGE2) in the hypothalamus, a key intermediate in thermoregulation. Additionally, paracetamol's metabolite, N-acylphenolamine (AM404), is proposed to interact with the endocannabinoid system, acting as an agonist on the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor and potentially the Cannabinoid 1 ( CB1) receptor, contributing to descending inhibitory pathways.

Phenylephrine functions as a direct-acting alpha1-adrenergic receptor agonist. This interaction, which is predominant in vascular smooth muscle, particularly in the nasal mucosa, initiates the G q protein signaling cascade. Activation of G q leads to the production of inositol trisphosphate ( IP3) and diacylglycerol (DAG), causing an increase in intracellular Ca^2+ concentration, resulting in vasoconstriction.

Ascorbic acid (Vitamin C) acts as a water-soluble antioxidant, neutralizing reactive oxygen species (ROS) and regenerating other antioxidants like alpha-tocopherol. It is also a necessary cofactor for various enzyme systems, including those involved in hydroxylation reactions.

Dosage and Administration Information

How to Use Фервекс

Fervex is intended for short-term oral administration, following standardized dosing guidelines. Its use is standardized by specific instructions regarding preparation, frequency, and maximum daily intake.


Administration and Dosage Protocol

Category Official Instruction (Adults and Adolescents 15 years)
Route of Administration Oral ingestion after reconstitution.
Single Dose One (1) sachet, containing 500 mg Paracetamol, 25 mg Pheniramine Maleate, and 200 mg Ascorbic Acid.
Maximum Daily Dose Three (3) sachets per 24-hour period.
Minimum Interval A minimum of four (4) hours must elapse between consecutive doses.
Preparation The granules must be dissolved in a sufficient quantity of water, which may be cold or hot.
Duration of Use Treatment should not exceed five (5) days (or 3 days for fever) without medical consultation.

Special Procedural Constraints

The usage protocol includes high-level constraints to ensure proper administration. The total daily intake of Paracetamol from all sources must be observed, making concurrent use with other Paracetamol- or antihistamine-containing products prohibited. Administration is advised preferably in the evening in the context of flu-like symptoms due to the presence of Pheniramine. For patients with severe renal impairment (creatinine clearance <10 mL/min), the minimum interval between doses is extended to eight (8) hours to account for reduced clearance.

Recent Clinical Evidence

Research evidence / Overview of studies for Фервекс

Evidence for Symptomatic Relief of Cold and Flu

Research has evaluated this medication, which combines Paracetamol, Pheniramine Maleate, and Ascorbic Acid, to see how it relates to patient-reported outcomes describing perceived discomfort and outcomes related to systemic or functional imbalance during periods of acute respiratory illness. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted during periods of increased symptom activity and were applied in studies examining patient-reported experiences.

Researchers used metrics like the Total Symptom Score (TSS), which measures the severity of multiple issues—including headache, body aches, elevated temperature, sneezing, and runny nose—during the symptomatic period. Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to these acute, disruptive episodes. Research contributes to the broader evidence landscape related to the overall symptom burden.


Focus of Clinical Studies: Symptom Outcomes Examined

The clinical trials relevant to this combination were evaluated in research exploring short-term symptom changes, with a particular focus on outcomes linked to inflammatory or irritative states, such as the runny nose and sneezing often seen in rhinitis. Research examined how symptoms evolved in populations dealing with conditions characterized by fluctuating or episodic manifestations like the common cold. Findings indicate patterns related to the time course of the product's effect on pain and temperature.


Long-term Follow-up and Duration of Data

Because this medication was studied for short-term symptomatic relief, research exploring how symptoms change over time typically focuses on the acute phase of illness. Follow-up durations were limited, with most controlled studies observing responses over defined time intervals of just a few days. Consequently, long-term effects are not fully established or characterized by the existing evidence.


Research in Specific Age Groups and Populations

Most clinical evidence for this type of symptomatic combination is derived from settings with varying symptom burdens, including adults and adolescents (typically aged 15 years and over). The results apply only to the populations studied under the conditions of the trials. Data for certain groups remain insufficient.


Understanding Evidence Gaps and Remaining Research Questions

The evidence base is heterogeneous, meaning that studies often evaluate slightly different combinations of active ingredients. The role of Ascorbic Acid (Vitamin C), included in this formulation, is an area where data are still emerging.

Key Studies & References

  1. APFLU - Paracetamol 500 mg, Pheniramine Maleate 25 mg, Ascorbic Acid 200 mg - Powder for suspension - SmPC - Rwanda FDA
  2. Common colds: Learn More – Relief for a stuffy nose, cough and sore throat - NCBI - NIH

Frequently Asked Questions (FAQ)

Common questions about Фервекс (FAQ)


Q: What makes Fervex different from other cold powders?

A: Fervex is defined in official regulatory documents as a fixed-dose combination product. It contains three active substances: Paracetamol (for pain and fever), Pheniramine Maleate (an antihistamine for congestion and sneezing), and Ascorbic Acid (Vitamin C). This specific combination of components distinguishes it from medications with fewer active ingredients.


Q: Can Fervex help with allergic rhinitis?

A: The medication includes Pheniramine Maleate, which is an H₁-antihistamine. This type of agent is described in pharmacological texts as relieving symptoms associated with rhinitis, such as a runny nose and sneezing. Its regulatory indication is primarily for the symptomatic relief of cold and flu, and any consideration for other uses should be managed by a healthcare provider.


Q: Is there a sugar-free Fervex?

A: Yes, official product information indicates that formulations are available which contain an alternative sweetener, such as aspartame, making them sugar-free. Regulatory documents specify that these specific formulations are not intended for individuals with the metabolic disorder Phenylketonuria.


Q: Can one drive or operate machinery after taking Fervex?

A: Official labeling advises that the medication can cause drowsiness (somnolence) and decreased attention, effects caused by the antihistamine component. Because of this risk, official labeling advises caution regarding activities like driving or operating heavy machinery.


Q: Can Fervex interact with anti-allergy drugs?

A: Fervex contains an antihistamine, and co-administration with other substances that have anticholinergic properties (including certain other anti-allergy drugs) requires caution. Using these together carries a risk of potentially increased side effects, such as dry mouth or difficulty urinating.


Q: Can Fervex be mixed with hot tea?

A: Official instructions state that the granules must be dissolved in a sufficient quantity of water, which may be cold or hot. While tea is primarily water, the regulatory guidelines only explicitly mention 'water' as the dissolution medium.


Q: Does Fervex affect blood pressure?

A: The product contains Phenylephrine, which acts as a vasoconstrictor (it narrows blood vessels), and this may have effects on circulation. Regulatory documents include special warnings for patients with uncontrolled high blood pressure (hypertension) or certain cardiovascular conditions.


Q: Can I take Fervex if I am taking antidepressants?

A: Regulatory information states that co-administration is formally contraindicated (must not be taken) with Monoamine Oxidase Inhibitors (MAOIs), which are a class of antidepressants. Caution is also advised when combining Fervex with other medications that cause central nervous system depression, a category that includes some other antidepressant classes.


Q: What is Fervex for, besides cold and flu symptoms?

A: The medication's regulatory indication is specific and limited to the symptomatic relief of illness associated with flu, the common cold, and related rhinitis (inflammation of the nasal passages) in adults and adolescents. Its regulatory indication focuses solely on the symptomatic relief of cold, flu, and related rhinitis.


Q: Can Fervex be taken just for a headache?

A: The active component Paracetamol has well-established analgesic (pain-relieving) properties. However, the regulatory indication for the combined product is for the symptomatic relief of the entire cold and flu syndrome, which often includes headache.


Q: Is Fervex with Vitamin C the same as the regular one?

A: Yes, the standard formulation of Fervex includes Ascorbic Acid (Vitamin C) as one of its three primary active ingredients. This means that 'Fervex' inherently contains Vitamin C, and there is no standard version without it.


Q: How long until Fervex starts working?

A: Pharmacokinetic data indicate that the maximum concentration of the Paracetamol component in the blood is typically reached within 30 minutes to one hour following administration. This measurement is an indicator of when the medicine is fully absorbed.


Q: Can Fervex be taken if there is no fever?

A: Yes, the medication is officially indicated for the symptomatic relief of cold and flu symptoms that can occur regardless of temperature. These include pain, headache, runny nose, and sneezing, which are addressed by the Paracetamol and Pheniramine components.


Q: Can the flavor (lemon, raspberry) affect Fervex's action?

A: Official regulatory information classifies flavorings and colorings as excipients—substances that are not pharmaceutically active. They are included in the formulation primarily to improve the product's acceptability and taste, and they are not described as influencing the medication's therapeutic effects.


Q: What should I do if my condition worsens after taking Fervex?

A: Official instructions specify that treatment should not exceed five days (or three days for fever). If symptoms persist, do not disappear, or worsen after the recommended duration of use, consulting a healthcare provider is appropriate.


Q: Is there a risk of addiction or dependence on Fervex?

A: The product is officially designated for short-term symptomatic use. Regulatory documents do not list dependence or addiction as known adverse effects when the medication is used for the indicated short-term, symptomatic relief.


Q: Can Fervex be taken with diabetes?

A: Patients with diabetes should be aware of the excipients in the product. Standard formulations contain sucrose (sugar), which may need consideration regarding dietary intake. Sugar-free formulations are available as an alternative.


Q: Can Fervex change blood test results?

A: Regulatory documents indicate that the Ascorbic Acid (Vitamin C) content, particularly in high doses, may interfere with certain laboratory tests. This interference can potentially alter the measurement of substances like creatinine and glucose.


Q: What is the difference between Fervex and 'Fervex for children', and what are the age limits for different forms?

A: The adult Fervex formulation is not intended for use in children under 15 years of age. Pediatric forms are manufactured as separate products. They feature different concentrations of the active components to align with specific age-appropriate dosing protocols.


Q: Is it true that Fervex can cause insomnia?

A: While the medication's antihistamine component typically causes drowsiness (somnolence), regulatory documents note that, in rare instances, paradoxical reactions may occur. These can include effects such as excitement, nervousness, or insomnia.


Q: If I take vitamins, will it affect Fervex?

A: Regulatory documents warn that using Fervex with other products (including certain vitamins or supplements) that contain its active components (Paracetamol, Pheniramine Maleate, or Ascorbic Acid) may lead to the risk of exceeding maximum daily limits.


Q: Can Fervex be taken on an empty stomach?

A: Official information does not prohibit taking Fervex without food. However, studies described in regulatory documents show that taking the medication on an empty stomach may accelerate the absorption of the Paracetamol component, potentially leading to a faster onset of action.


Q: How long does the pain relief effect of Fervex last?

A: The duration of the analgesic effect, based on the Paracetamol component, is generally consistent with the recommended minimum dosing interval of four hours. This interval ensures that concentrations remain within the therapeutic range.


Q: Why does Fervex contain colorings and flavorings?

A: Colorings and flavorings are classified as excipients in the formulation. According to official documents, their purpose is to ensure the product's acceptability, improve its taste (organoleptic qualities), and comply with quality control standards.


Q: Why is Fervex not recommended for glaucoma?

A: The medication contains Pheniramine Maleate, which has anticholinergic properties. Due to its anticholinergic properties, the medication is not recommended for use in the presence of angle-closure glaucoma, as this class of agents has the potential to increase internal eye pressure.

How should Фервекс be stored and disposed of?

How to Store and Dispose of Fervex

The storage of Fervex (granules in a sachet) must adhere to official regulatory conditions to maintain product stability. The medicine must be kept out of the reach and sight of children at all times.

Storage Conditions

Fervex must be stored within a defined temperature range, typically not exceeding 25°C or 30°C, depending on the specific regulatory label. The product must be protected away from heat and moisture and should be kept in its original packaging. Do not use the medicine after the labeled expiry date.

Disposal Instructions

Expired or unused Fervex must be disposed of in accordance with local regulations; it must not be discarded in household waste or flushed down the drain. To ensure proper environmental protection, return the unused product to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Фервекс found in:

A-Z Index: